![AdAlta](/sites/default/files/styles/medium/public/bn-di-company/32075-adalta.png?itok=ecxRppKR)
AdAlta Ltd (1AD) is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein.